Abstract:Objective To systematically explore the targets and signaling pathways of sinomenine (SIN) in the treatment of osteoarthritis (OA) using integrated network pharmacology, molecular docking, and experimental validation. Methods The TCMSP, SwissADME, and Pharmmapper databases were used to predict SIN targets, while the databases of GeneCards, DisGeNET, OMIM, and DrugBank were selected to acquire OA targets. Subsequently, the intersection targets of SIN and OA disease were collected using the Veeny platform. Then, the protein-protein interaction (PPI) network map of “SIN-targets-OA” was established using String database and Cytoscape software. Additionally, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed through the Database for Annotation, Visualization and Integrated Discovery (DAVID). Additionally, the potential proteins of SIN against OA were validated via molecular docking technique. Finally, the experimental validation was performed in SW1353 cells induced by interleukin (IL)-1β. Results A total of 315 potential targets of SIN and 4300 OA-associated targets were collected from public databases, and 42 intersecting potential targets of SIN and OA disease acquired. Then, the PPI network diagram of “SIN-targets-OA” was acquired that comprised a total of 43 nodes and 82 edges. Moreover, 173 GO and 21 KEGG pathway entries were screened with a P-value <.05. Among them, peroxisome proliferator-activated receptor (PPAR) and IL-17 are the core signaling pathways. Molecular docking technique indicated strong binding energies of SIN with PPAR (−6.1 kcal/mol) and IL-17 (−6.3 kcal/mol). Lastly, SIN at the concentration of 50 μmol/L has a significant effect on IL-1β-induced SW1353 cells by the inhibition of PPAR-γ and IL-17A proteins without cytotoxicity. Conclusion This work revealed the underlying targets and signaling pathways of SIN against OA using integrated network pharmacology molecular docking, and experimental validation. These findings provide scientific evidence for the clinical application of SIN for OA treatment.

From mundane to classic: Sinomenine as a multi‐therapeutic agent

Research, Development and Pharmacological Activity of Sinomenine and Its Derivatives

Bioactivities and Mechanisms of Action of Sinomenine and Its Derivatives: A Comprehensive Review

A systematic review: Sinomenine

Advances in Anti-Inflammatory and Immunoregulatory Mechanisms of Sinomenine

Sinomenine in Cardio-Cerebrovascular Diseases: Potential Therapeutic Effects and Pharmacological Evidences

Rapid Characterization of the Potential Active of Sinomenine in Rats by Ultra‐High‐Performance Liquid Chromatography‐Quadrupole‐Exactive Orbitrap Mass Spectrometry and Molecular Docking

Pharmacological mechanisms of sinomenine in anti-inflammatory immunity and osteoprotection in rheumatoid arthritis: A systematic review

Potential therapeutic effects and pharmacological evidence of sinomenine in central nervous system disorders

Metabolic mechanism and anti-inflammation effects of sinomenine and its major metabolites N-demethylsinomenine and sinomenine-N-oxide

The anti-tumor potential of sinomenine: a narrative review

Recent Advances in the Therapeutic Potential of Sinomenine for Cancer Treatment

Multifunctional nanoparticles of sinomenine hydrochloride for treat-to-target therapy of rheumatoid arthritis via modulation of proinflammatory cytokines

Sinomenine regulates immune cell subsets: Potential neuro-immune intervene for precise treatment of chronic pain

Sinomenine Activation of Nrf2 Signaling Prevents Hyperactive Inflammation and Kidney Injury in a Mouse Model of Obstructive Nephropathy.

Integrated Network Pharmacology, Molecular Docking, and Experimental Validation to Explore Potential Mechanisms of Sinomenine in the Treatment of Osteoarthritis

Sinomenine Alleviates Rheumatoid Arthritis by Suppressing the PI3K-Akt Signaling Pathway, as Demonstrated Through Network Pharmacology, Molecular Docking, and Experimental Validation

Integrated multi-omics and bioinformatic methods to reveal the mechanisms of sinomenine against diabetic nephropathy

Sinomenine Ameliorated Microglial Activation and Neuropathic Pain After Chronic Constriction Injury Via TGF‐β1/ALK5/Smad3 Signalling Pathway

Sinomenine hydrochloride bidirectionally inhibits progression of tumor and autoimmune diseases by regulating AMPK pathway

Design, Synthesis, Biological Evaluation and Silico Prediction of Novel Sinomenine Derivatives.